New Era Energy & Digital Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $3.44 (market cap $518.22M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 20.3× New Era Energy & Digital Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, New Era Energy & Digital Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 2 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NUAI | PCVX | |
|---|---|---|
Market Cap | $518.22M | $10.51B |
Volume | 7,267,523 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $8.06 | $73.82 |
52-Week Low | $2.37 | $40.32 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $463.57M | $9.14B |
Signals from Pluang's Aura AI — not financial advice
NUAI trades at $4.29, down 1.15% today, with a bearish technical signal despite recent positive news about a 20-year power deal for its Texas data center project. The company shows severe financial stress with negative margins (-5,985.71% net income margin) and consecutive quarterly losses, though analyst consensus remains bullish with a $10.67 price target. Recent institutional interest includes BlackRock's new stake in Q2 2026.
The stock presents high-risk speculation with potential upside if data center development succeeds, but faces substantial execution and funding risks. Current fundamentals are weak, making it suitable only for risk-tolerant investors betting on future project milestones and hyperscaler partnerships.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →